Yulong Fu1,2†
Anqi Wang1,2†Jieqi Zhou1,2Wei Feng1Minhua Shi3Xiao Xu4Hongqing Zhao5Liming Cai6Jian Feng7Xuedong Lv8Xiaodong Zhang9Wenjing Xu10Zhengrong Zhang11Guoer Ma12Jian Wang13Tong Zhou14Dahai Zhao15Haohui Fang16
Zeyi Liu1,2,17*Jian-an Huang1,2,17*- 1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China
- 2Suzhou Key Laboratory for Respiratory Diseases, Suzhou, China
- 3Department of Respiratory Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, China
- 4Department of Respiratory Medicine, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
- 5Department of Respirology, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, China
- 6Department of Respiratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China
- 7Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, China
- 8Department of Respiratory Medicine, The Second Affiliated Hospital of Nantong University, Nantong, China
- 9Department of Medical Oncology, Nantong Tumor Hospital, Nantong, China
- 10Departments of Respiratory Medicine, Northern Jiangsu People’s Hospital, Clinical Medical College of Yangzhou University, Yangzhou, China
- 11Department of Respiratory Medicine, First People’s Hospital of Yangzhou City, Yangzhou, China
- 12Department of Respiratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China
- 13Department of Respiratory Medicine, Zhenjiang First People’s Hospital, Zhenjiang, China
- 14Department of Oncology, Changzhou Cancer Hospital Affiliated to Soochow University, Changzhou, China
- 15Department of Respiratory and Critical Care Medicine, The Second Hospital of Anhui Medical University, Hefei, China
- 16Department of Respiratory Medicine, Anhui Chest Hospital, Hefei, China
- 17Institute of Respiratory Diseases, Soochow University, Suzhou, China
by Fu Y, Wang A, Zhou J, Feng W, Shi M, Xu X, Zhao H, Cai L, Feng J, Lv X, Zhang X, Xu W, Zhang Z, Ma G, Wang J, Zhou T, Zhao D, Fang H, Liu Z and Huang J-a (2021) Front. Oncol. 11:621992. doi: 10.3389/fonc.2021.621992
Error in Figure/Table Legend
In the published article, there was an error in the legend for Figure 4 as published. The number of the patient was wrong. The corrected legend appears below.
Illustration of the genotype data and treatment received by patient No. 45 along with representative CT scans at the time points indicated.
Error in Figure/Table Legend
In the published article, there was an error in the legend for Figure 5 as published. The number of the patient was wrong. The corrected legend appears below.
Illustration of the genotype data and treatment received by patient No. 17 along with representative CT scans at the time points indicate.
Text Correction
In the published article, there was an error. The number of patients from different sexes were wrong.
A correction has been made to 3. RESULTS, 3.1 Mutation detection in oncogenes after resistance, Paragraph 1. This sentence previously stated:
“A total of 50 patients from 15 hospitals, including 27 females and 23 males, were recruited for our investigation.”
The corrected sentence appears below:
“A total of 50 patients from 15 hospitals, including 27 males and 23 females, were recruited for our investigation.”
Text Correction
In the published article, there was an error. The description of patient No.17 was inconsistent with the content of the Figures.
A correction has been made to 3. RESULTS, 3.4 Potential resistance mechanisms to osimertinib treatment, Paragraph 2. This sentence previously stated:
“First, chemotherapy with cisplatin and pemetrexed was used for a total of 7 months until mediastinal lymph node enlargement was observed. Gefitinib was then administered, being optimally tolerated at the beginning. However, after 4 months, gefitinib was discontinued because of disease progression, as shown in Figure 4. A rebiopsy revealed EGFR T790M, TP53 R273C mutation, and EGFR amplification, with persistence of EGFR ex19del. The patient then commenced a new treatment with osimertinib. However, her condition rapidly declined, and she died 1 month later.”
The corrected sentence appears below:
“The patient was initially treated with first-generation EGFR-TKI gefitinib since EGFR exon 19 deletion was detected upon diagnosis biopsy. However, disease progressed 32 months after occurrence, as shown in Figure 5. A rebiopsy revealed EGFR T790M, TP53 R273C mutation, and EGFR amplification, with persistence of EGFR ex19del. Hence, second-line treatment with osimertinib was carried out. Unfortunately, disease progression occurred 3 months later, treatment with osimertinib was discontinued.”
Text Correction
In the published article, there was an error. The description of patient No.45 were inconsistent with the content of the Figures.
A correction has been made to 3. RESULTS, 3.4 Potential resistance mechanisms to osimertinib treatment, Paragraph 3. This sentence previously stated:
“The patient was initially treated with first-generation EGFR-TKI gefitinib since EGFR exon 19 deletion was detected upon diagnosis biopsy. However, disease progression occurred 32 months after treatment initiation, as shown in Figure 5. The subsequent rebiopsy results confirmed ex19del and revealed the emergence of EGFR T790M, KRAS G12V, and TP53 G244D mutations. Hence, second-line treatment with osimertinib was carried out. Unfortunately, disease progression occurred 3 months later, treatment with osimertinib was discontinued,”
The corrected sentence appears below:
“First, chemotherapy with cisplatin and pemetrexed was used for a total of 7 months until mediastinal lymph node enlargement was observed. Gefitinib was then administered, being optimally tolerated at the beginning. However, after 4 months, gefitinib was discontinued because of disease progression, as shown in Figure 4. The subsequent rebiopsy results confirmed ex19del and revealed the emergence of EGFR T790M, KRAS G12V, and TP53 G244D mutations. The patient then commenced a new treatment with osimertinib. However, his condition rapidly declined,”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: non-small cell lung cancer, liquid biopsy, gene sequencing, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), drug resistance
Citation: Fu Y, Wang A, Zhou J, Feng W, Shi M, Xu X, Zhao H, Cai L, Feng J, Lv X, Zhang X, Xu W, Zhang Z, Ma G, Wang J, Zhou T, Zhao D, Fang H, Liu Z and Huang J-a (2023) Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy. Front. Oncol. 13:1236311. doi: 10.3389/fonc.2023.1236311
Received: 07 June 2023; Accepted: 14 June 2023;
Published: 27 June 2023.
Edited and Reviewed by:
Shiv K Gupta, Mayo Clinic, United StatesCopyright © 2023 Fu, Wang, Zhou, Feng, Shi, Xu, Zhao, Cai, Feng, Lv, Zhang, Xu, Zhang, Ma, Wang, Zhou, Zhao, Fang, Liu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zeyi Liu, liuzeyisuda@163.com; Jian-an Huang, huang_jian_an@163.com
†These authors have contributed equally to this work